Treatment of advanced Parkinson's disease

Current Opinion in Neurology

Volumn 27, Issue 4, 2014, Pages 450-460

  Giugni, Juan C ^a   Okun, Michael S ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

behavioral; deep brain stimulation; medications; Parkinson's disease; selection criteria

Indexed keywords

APOMORPHINE; CARBIDOPA PLUS LEVODOPA; ANTIPARKINSON AGENT; LEVODOPA;

ANXIETY; APATHY; AUTONOMIC DYSFUNCTION; BALANCE DISORDER; BRAIN DEPTH STIMULATION; COMPARATIVE STUDY; DEMENTIA; DEPRESSION; DISEASE MANAGEMENT; DYSKINESIA; GAIT DISORDER; HALLUCINATION; HUMAN; INVASIVE PROCEDURE; NON INVASIVE PROCEDURE; PAIN; PARKINSON DISEASE; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SLEEP DISORDER;

ANTIPARKINSON AGENTS; HUMANS; LEVODOPA; PARKINSON DISEASE;

EID: 84904053430     PISSN: 13507540     EISSN: 14736551     Source Type: Journal    
DOI: 10.1097/WCO.0000000000000118     Document Type: Review

References (108)

1. Shulman LM, Gruber-Baldini AL, Anderson KE, et al. The evolution of disability in Parkinson disease. Mov Disord 2008; 23:790-796.
2. Hauser RA, McDermott MP, Messing S. Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease. Arch Neurol 2006; 63:1756-1760.
3. Hely MA, Morris JG, Reid WG, Trafficante R. Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord 2005; 20:190-199.
4. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967; 17:427-442.
5. Hoehn MM. Parkinsonism treated with levodopa: progression and mortality. J Neural Transm Suppl 1983; 19:253-264.
6. Chapuis S, Ouchchane L, Metz O, et al. Impact of the motor complications of Parkinson's disease on the quality of life. Mov Disord 2005; 20:224-230.
7. Pechevis M, Clarke CE, Vieregge P, et al. Effects of dyskinesias in Parkinson's disease on quality of life and health-related costs: a prospective European study. Eur J neurol 2005; 12:956-963.
8. Santos-Garcia D, de la Fuente-Fernandez R. Impact of non-motor symptoms on health-related and perceived quality of life in Parkinson's disease. J Neurol Sci 2013; 332:136-140.
9. Papapetropoulos S, Mash DC. Motor fluctuations and dyskinesias in advanced/end stage Parkinson's disease: a study from a population of brain donors. J Neural Transm 2007; 114:341-345.
10. Schrag A, Dodel R, Spottke A, et al. Rate of clinical progression in Parkinson's disease. a prospective study. Mov Disord 2007; 22:938-945.
11. Coelho M, Ferreira JJ. Late-stage Parkinson disease. Nat Rev Neurol 2012; 8:435-442.
12. Lang AE, Lozano AM. Parkinson's disease. second of two parts. N Engl J Med 1998; 339:1130-1143.
13. Deleu D, Northway MG, Hanssens Y. Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease. Clin Pharmacokinet 2002; 41:261-309.
14. Antonini A, Chaudhuri KR, Martinez-Martin P, Odin P. Oral and infusion levodopa-based strategies for managing motor complications in patients with Parkinson's disease. CNS Drugs 2010; 24:119-129.
15. Pilleri M, Antonini A. Novel levodopa formulations in the treatment of Parkinson's disease. Expert Rev Neurother 2014; 14:143-149.
16. Grosset KA, Reid JL, Grosset DG. Medicine-taking behavior: implications of suboptimal compliance in Parkinson's disease. Mov Disord 2005; 20:1397-1404.
17. Lieberman A, Gopinathan G, Miller E, et al. Randomized double-blind crossover study of Sinemet-controlled release (CR4 50/200) versus Sinemet 25/ 100 in Parkinson's disease. Eur Neurol 1990; 30:75-78.
18. Pahwa R, Factor SA, Lyons KE, et al. Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidencebased review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006; 66:983-995.
19. Hauser RA, Hsu A, Kell S, et al. Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial. Lancet Neurol 2013; 12:346-356.
20. Fox SH, Katzenschlager R, Lim SY, et al. The Movement Disorder Society Evidence-Based Medicine Review Update: treatments for the motor symptoms of Parkinson's disease. Mov Disord 2011; 26 (Suppl 3):S2-41.
21. Parkinson Study G. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 2005; 62:241-248.
22. Rascol O, Brooks DJ, Melamed E, et al. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, lasting effect in adjunct therapy with Rasagiline given once daily, study): a randomised, double-blind, parallel-group trial. Lancet 2005; 365:947-954.
23. Elmer LW. Rasagiline adjunct therapy in patients with Parkinson's disease: post hoc analyses of the PRESTO and LARGO trials. Parkinsonism Relat Disord 2013; 19:930-936.
24. Olanow CW, Rascol O, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med 2009; 361:1268-1278.
25. Shoulson I, Oakes D, Fahn S, et al. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Ann Neurol 2002; 51:604-612.
26. Brooks DJ, Leinonen M, Kuoppamaki M, Nissinen H. Five-year efficacy and safety of levodopa/DDCI and entacapone in patients with Parkinson's disease. J Neural Transm 2008; 115:843-849.
27. Tolosa E, Hernandez B, Linazasoro G, et al. Efficacy of levodopa/carbidopa/ entacapone versus levodopa/carbidopa in patients with early Parkinson's disease experiencing mild wearing-off: a randomised, double-blind trial. J Neural Transm 2014; 121:357-366.
28. Stocchi F. The levodopa wearing-off phenomenon in Parkinson's disease: pharmacokinetic considerations. Expert Opin Pharmacother 2006; 7:1399-1407.
29. Stocchi F, Rascol O, Kieburtz K, et al. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol 2010; 68:18-27.
30. Hauser RA, Panisset M, Abbruzzese G, et al. Double-blind trial of levodopa/ carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease. Mov Disord 2009; 24:541-550.
31. Graham DJ, Williams JR, Hsueh YH, et al. Cardiovascular and mortality risks in Parkinson's disease patients treated with entacapone. Mov Disord 2013; 28:490-497.
32. Schapira AH, Barone P, Hauser RA, et al. Patient-reported convenience of once-daily versus three-times-daily dosing during long-term studies of pramipexole in early and advanced Parkinson's disease. Eur J Neurol 2013; 20:50-56.
33. Yun JY, Kim HJ, Lee JY, et al. Comparison of once-daily versus twice-daily combination of ropinirole prolonged release in Parkinson's disease. BMC Neurol 2013; 13:113.
34. Olanow CW, Obeso JA, Stocchi F. Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurol 2006; 5:677-687.
35. Olanow CW, Obeso JA, Stocchi F. Drug insight: continuous dopaminergic stimulation in the treatment of Parkinson's disease. Nat Clin Pract Neurol 2006; 2:382-392.
36. Schapira AH, Barone P, Hauser RA, et al. Extended-release pramipexole in advanced Parkinson disease: a randomized controlled trial. Neurology 2011; 77:767-774.
37. Stocchi F, Giorgi L, Hunter B, Schapira AH. PREPARED: comparison of prolonged and immediate release ropinirole in advanced Parkinson's disease. Mov Disord 2011; 26:1259-1265.
38. LeWitt PA, Lyons KE, Pahwa R, Group SPS. Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study. Neurology 2007; 68:1262-1267.
39. Poewe WH, Rascol O, Quinn N, et al. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, doubledummy, randomised controlled trial. Lancet Neurol 2007; 6:513-520.
40. Trenkwalder C, Kies B, Rudzinska M, et al. Rotigotine effects on early morning motor function and sleep in Parkinson's disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord 2011; 26: 90-99.
41. LeWitt PA, Boroojerdi B, Surmann E, et al. Rotigotine transdermal system for long-termtreatment of patients with advanced Parkinson's disease: results of two open-label extension studies, CLEOPATRA-PD and PREFER. J Neural Transm 2013; 120:1069-1081.
42. Lyons KE, Pahwa R. Outcomes of rotigotine clinical trials: effects on motor and nonmotor symptoms of Parkinson's disease. Neurol Clin 2013; 31 (Suppl 3):S51-S59.
43. Perez-Lloret S, Rey MV, Fabre N, et al. Prevalence and pharmacological factors associated with impulse-control disorder symptoms in patients with Parkinson disease. Clin Neuropharmacol 2012; 35:261-265.
44. Garcia-Ruiz PJ, Martinez Castrillo JC, Alonso-Canovas A, et al. Impulse control disorder in patients with Parkinson's disease under dopamine agonist therapy: a multicentre study. J Neurol Neurosurg Psychiatry 2014. [Epub ahead of print]
45. LeWitt PA, Guttman M, Tetrud JW, et al. Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces 'off' time in Parkinson's disease: a doubleblind, randomized, multicenter clinical trial (6002-US-005). Ann Neurol 2008; 63:295-302.
46. Stacy M, Silver D, Mendis T, et al. A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease. Neurology 2008; 70:2233-2240.
47. Hauser RA, Shulman LM, Trugman JM, et al. Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations. Mov Disord 2008; 23:2177-2185.
48. Mizuno Y, Kondo T; Japanese Istradefylline Study G. Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson's disease. Mov Disord 2013; 28:1138-1141.
49. Politis M, Wu K, Molloy S, et al. Parkinson's disease symptoms: the patient's perspective. Mov Disord 2010; 25:1646-1651.
50. Rodnitzky RL, Narayanan NS. Amantadine's role in the treatment of levodopainduced dyskinesia. Neurology 2014; 82:288-289.
51. Bargiotas P, Konitsiotis S. Levodopa-induced dyskinesias in Parkinson's disease: emerging treatments. Neuropsychiatr Dis Treat 2013; 9:1605-1617.
52. Stocchi F, Rascol O, Destee A, et al. AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study. Mov Disord 2013; 28:1838-1846.
53. Volkmann J, Albanese A, Antonini A, et al. Selecting deep brain stimulation or infusion therapies in advanced Parkinson's disease: an evidence-based review. J Neurol 2013; 260:2701-2714.
54. Pfeiffer RF, Gutmann L, Hull KL Jr, et al. Continued efficacy and safety of subcutaneous apomorphine in patients with advanced Parkinson's disease. Parkinsonism Relat Disord 2007; 13:93-100.
55. DeGaspari D, Siri C, Landi A, et al. Clinical and neuropsychological follow up at 12 months in patients with complicated Parkinson's disease treated with subcutaneous apomorphine infusion or deep brain stimulation of the subthalamic nucleus. J Neurol Neurosurg Psychiatry 2006; 77:450-453.
56. Garcia Ruiz PJ, Sesar Ignacio A, Ares Pensado B, et al. Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: a multicenter study. Mov Disord 2008; 23:1130-1136.
57. Morgante L, Basile G, Epifanio A, et al. Continuous apomorphine infusion (CAI) and neuropsychiatric disorders in patients with advanced Parkinson's disease: a follow-up of two years. Arch Gerontol Geriatr Suppl 2004; 9: 291-296.
58. Martinez-Martin P, Reddy P, Antonini A, et al. Chronic subcutaneous infusion therapy with apomorphine in advanced Parkinson's disease compared to conventional therapy: a real life study of non motor effect. J Parkinson's Dis 2011; 1:197-203.
59. Antonini A, Odin P. Pros and cons of apomorphine and L-dopa continuous infusion in advanced Parkinson's disease. Parkinsonism Relat Disord 2009; 15 (Suppl 4):S97-100.
60. Nyholm D. Duodopa1 treatment for advanced Parkinson's disease: a review of efficacy and safety. Parkinsonism Relat Disord 2012; 18:916-929.
61. Foltynie T, Magee C, James C, et al. Impact of Duodopa on quality of life in advanced Parkinson's disease: a UK case series. Parkinson's Dis 2013; 2013:362908.
62. Fernandez HH, Vanagunas A, Odin P, et al. Levodopa-carbidopa intestinal gel in advanced Parkinson's disease open-label study: interim results. Parkinsonism Relat Disord 2013; 19:339-345.
63. Olanow CW, Kieburtz K, Odin P, et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol 2014; 13:141-149.
64. Deuschl G, Schade-Brittinger C, Krack P, et al. A randomized trial of deepbrain stimulation for Parkinson's disease. N Engl J Med 2006; 355:896-908.
65. Weaver FM, Follett K, Stern M, et al. Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. JAMA 2009; 301:63-73.
66. Williams A, Gill S, Varma T, et al. Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson's disease (PD SURG trial): a randomised, open-label trial. Lancet Neurol 2010; 9:581-591.
67. Okun MS, Foote KD. Subthalamic nucleus vs globus pallidus interna deep brain stimulation, the rematch: will pallidal deep brain stimulation make a triumphant return? Arch Neurol 2005; 62:533-536.
68. Okun MS, Fernandez HH, Wu SS, et al. Cognition and mood in Parkinson's disease in subthalamic nucleus versus globus pallidus interna deep brain stimulation: the COMPARE trial. Ann Neurol 2009; 65:586-595.
69. Follett KA, Weaver FM, Stern M, et al. Pallidal versus subthalamic deep-brain stimulation for Parkinson's disease. N Engl J Med 2010; 362:2077-2091.
70. Odekerken VJ, van Laar T, Staal MJ, et al. Subthalamic nucleus versus globus pallidus bilateral deep brain stimulation for advanced Parkinson's disease (NSTAPS study): a randomised controlled trial. Lancet Neurol 2013; 12:37-44.
71. Sako W, Miyazaki Y, Izumi Y, Kaji R. Which target is best for patients with Parkinson's disease? A meta-analysis of pallidal and subthalamic stimulation. J Neurol Neurosurg Psychiatry 2014. [Epub ahead of print]
72. Okun MS, Foote KD. Parkinson's disease DBS: what, when, who and why? The time has come to tailor DBS targets. Expert Rev Neurother 2010; 10:1847-1857.
73. Martinez-Ramirez D, Okun MS. Rationale and clinical pearls for primary care doctors referring patients for deep brain stimulation. Gerontology 2014; 60:38-48.
74. Bernal-Pacheco O, Oyama G, Foote KD, et al. Taking a better history for behavioral issues pre and postdeep brain stimulation: issues missed by standardized scales. Neuromodulation 2013; 16:35-39.
75. Rocchi L, Carlson-Kuhta P, Chiari L, et al. Effects of deep brain stimulation in the subthalamic nucleus or globus pallidus internus on step initiation in Parkinson disease: laboratory investigation. J Neurosurg 2012; 117:1141-1149.
76. Moro E, Hamani C, Poon YY, et al. Unilateral pedunculopontine stimulation improves falls in Parkinson's disease. Brain 2010; 133 (Pt 1):215-224.
77. Weiss D, Walach M, Meisner C, et al. Nigral stimulation for resistant axial motor impairment in Parkinson's disease? A randomized controlled trial. Brain 2013; 136 (Pt 7):2098-2108.
78. Ferraye MU, Debu B, Fraix V, et al. Effects of pedunculopontine nucleus area stimulation on gait disorders in Parkinson's disease. Brain 2010; 133 (Pt 1):205-214.
79. Allen NE, Sherrington C, Paul SS, Canning CG. Balance and falls in Parkinson's disease: a meta-analysis of the effect of exercise and motor training. Mov Disord 2011; 26:1605-1615.
80. Li F, Harmer P, Fitzgerald K, et al. Tai chi and postural stability in patients with Parkinson's disease. N Engl J Med 2012; 366:511-519.
81. Seppi K, Weintraub D, Coelho M, et al. The Movement Disorder Society Evidence-Based Medicine Review Update: treatments for the nonmotor symptoms of Parkinson's disease. Mov Disord 2011; 26 (Suppl 3):S42-80.
82. Goldman JG, Holden S. Treatment of psychosis and dementia in Parkinson's disease. Curr Treat Options Neurol 2014; 16:281.
83. Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004; 351:2509-2518.
84. Poewe W, Wolters E, Emre M, et al. Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: an active treatment extension study. Mov Disord 2006; 21:456-461.
85. Emre M, Poewe W, De Deyn PP, et al. Long-term safety of rivastigmine in Parkinson disease dementia: an open-label, randomized study. Clin Neuropharmacol 2014; 37:9-16.
86. Ravina B, Putt M, Siderowf A, et al. Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study. J Neurol Neurosurg Psychiatry 2005; 76:934-939.
87. Litvinenko IV, Odinak MM, Mogil'naia VI, Emelin A. [Efficacy and safety of galantamine (reminyl) in the treatment of dementia in patients with Parkinson's disease (open-label controlled trial)]. Zhurnal nevrologii i psikhiatrii imeni SS Korsakova/Ministerstvo zdravookhraneniia i meditsinskoi promyshlennosti Rossiiskoi Federatsii, Vserossiiskoe obshchestvo nevrologov [i] Vserossiiskoe obshchestvo psikhiat. [in Russian]. Zh Nevrol Psikhiatr Im S S Korsakova 2007; 107:25-33.
88. Emre M, Tsolaki M, Bonuccelli U, et al. Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010; 9:969-977.
89. Meltzer HY, Mills R, Revell S, et al. Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of Parkinson's disease psychosis. Neuropsychopharmacology 2010; 35:881-892.
90. Cummings J, Isaacson S, Mills R, et al. Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet 2014; 383:533-540.
91. Liu J, Dong J, Wang L, et al. Comparative efficacy and acceptability of antidepressants in Parkinson's disease: a network meta-analysis. PLoS One 2013; 8:e76651.
92. Troeung L, Egan SJ, Gasson N. A meta-analysis of randomised placebocontrolled treatment trials for depression and anxiety in Parkinson's disease. PLoS One 2013; 8:e79510.
93. Chatterjee A, Fahn S. Methylphenidate treats apathy in Parkinson's disease. J Neuropsychiatry Neurosci 2002; 14:461-462.
94. Czernecki V, Pillon B, Houeto JL, et al. Motivation, reward, and Parkinson's disease: influence of dopatherapy. Neuropsychologia 2002; 40:2257-2267.
95. Devos D, Moreau C, Maltete D, et al. Rivastigmine in apathetic but dementia and depression-free patients with Parkinson's disease: a double-blind, placebo-controlled, randomised clinical trial. J Neurol Neurosurg Psychiatry 2014; 85:668-674.
96. Sanchez-Ferro A, Benito-Leon J, Gomez-Esteban JC. The management of orthostatic hypotension in Parkinson's disease. Front Neurol 2013; 4: 64.
97. Mostile G, Jankovic J. Treatment of dysautonomia associated with Parkinson's disease. Parkinsonism Relat Disord 2009; 15 (Suppl 3):S224-S232.
98. Hauser RA, Hewitt LA, Isaacson S. Droxidopa in patients with neurogenic orthostatic hypotension associated with Parkinson's disease (NOH306A). J Parkinsons Dis 2014; 4:57-65.
99. Ozekmekci S, Apaydin H, Kilic E. Clinical features of 35 patients with Parkinson's disease displaying REM behavior disorder. Clin Neurol Neurosurg 2005; 107:306-309.
100. Boeve BF, Silber MH, Ferman TJ. Melatonin for treatment of REM sleep behavior disorder in neurologic disorders: results in 14 patients. Sleep Med 2003; 4:281-284.
101. Rios Romenets S, Creti L, Fichten C, et al. Doxepin and cognitive behavioural therapy for insomnia in patients with Parkinson's disease-a randomized study. Parkinsonism Relat Disord 2013; 19:670-675.
102. Beiske AG, Loge JH, Ronningen A, Svensson E. Pain in Parkinson's disease: prevalence and characteristics. Pain 2009; 141:173-177.
103. Sophie M, Ford B. Management of pain in Parkinson's disease. CNS Drugs 2012; 26:937-948.
104. Rana AQ, Kabir A, Jesudasan M, et al. Pain in Parkinson's disease: analysis and literature review. Clin Neurol Neurosurg 2013; 115:2313-2317.
105. Troche MS, Okun MS, Rosenbek JC, et al. Aspiration and swallowing in Parkinson disease and rehabilitation with EMST: a randomized trial. Neurology 2010; 75:1912-1919.
106. Ramig LO, Sapir S, Countryman S, et al. Intensive voice treatment (LSVT) for patients with Parkinson's disease: a 2 year follow up. J Neurol Neurosurg Psychiatry 2001; 71:493-498.
107. Foster ER, Bedekar M, Tickle-Degnen L. Systematic review of the effectiveness of occupational therapy-related interventions for people with Parkinson's disease. Am J Occu Ther 2014; 68:39-49.
108. van der Kolk NM, King LA. Effects of exercise on mobility in people with Parkinson's disease. Mov Disord 2013; 28:1587-1596.